Showing 1 - 8 results of 8 for search 'Hong-Shuai Li', query time: 0.04s Refine Results
  1. 1
    Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment

    Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment by Hong-Shuai Li, Guang-Jian Yang, Yan Wang

    Published 2021-04-01
    Get full text
    Article
  2. 2
    RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma

    RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma by Hong‐Shuai Li, Cheng‐Ming Liu, Yan Wang

    Published 2023-05-01
    Get full text
    Article
  3. 3
    Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

    Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review by Hong-Shuai Li, Hong-Shuai Li, Li-Li Yang, Ming-Yi Zhang, Ming-Yi Zhang, Ke Cheng, Ye Chen, Ji-Yan Liu, Ji-Yan Liu

    Published 2020-10-01
    Get full text
    Article
  4. 4
    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations

    A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations by Hong‐Shuai Li, Jin‐Yao Zhang, Xiang Yan, Hai‐Yan Xu, Xue‐Zhi Hao, Pu‐Yuan Xing, Yan Wang

    Published 2022-02-01
    Get full text
    Article
  5. 5
    Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review

    Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review by Hong-Shuai Li, Si-Yu Lei, Jun-Ling Li, Pu-Yuan Xing, Xue-Zhi Hao, Fei Xu, Hai-Yan Xu, Yan Wang

    Published 2022-08-01
    Get full text
    Article
  6. 6
    Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer

    Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer by Si‐Yu Lei, Hai‐Yan Xu, Hong‐Shuai Li, Ya‐Ning Yang, Fei Xu, Jun‐Ling Li, Zhi‐Jie Wang, Pu‐Yuan Xing, Xue‐Zhi Hao, Yan Wang

    Published 2023-08-01
    Get full text
    Article
  7. 7
    Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

    Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China by Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang

    Published 2022-06-01
    Get full text
    Article
  8. 8
    Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Comparative Cohort Study in China (AFANDA Study)

    Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon <i>EGFR</i> Mutations: A Co... by Hong-Shuai Li, Shou-Zheng Wang, Hai-Yan Xu, Xiang Yan, Jin-Yao Zhang, Si-Yu Lei, Teng Li, Xue-Zhi Hao, Tao Zhang, Guang-Jian Yang, Li-Qiang Zhou, Peng Liu, Yu-Ying Wang, Xing-Sheng Hu, Pu-Yuan Xing, Yan Wang

    Published 2022-10-01
    Get full text
    Article

Search Tools: